A Phase 1 Clinical Study of GC012F Injection in Subjects with Relapsed/Refractory Multiple Myeloma
| Title | A Phase 1 Clinical Study of GC012F Injection in Subjects with Relapsed/Refractory Multiple Myeloma |
|---|---|
| Description | This is a single-arm, non-randomized, open-trial clinical study to evaluate the safety and efficacy of GC012F in patients with relapsed refractory multiple myeloma. 10 evaluable subjects were dosed. Fluorescence in situ hybridization (FISH) is used to identify people at high risk for myeloma. Users can analyze the CAR copy number in the cells according to the derived data to determine whether the relevant CAR T cell products meet the requirements. This indicator is tested to prevent the risk of secondary tumors. |
| Organism | Homo sapiens |
| Data Type | Genetic Biomarkers |
| Data Accessibility | Controlled-access |
| BioProject | PRJCA025200 |
| Release Date | 2024-04-13 |
| Submitter | siyu huang (siyu.huang@gracellbio.com) |
| Organization | Gracell Biotechnologies (Shanghai) Co., Ltd. |
| Submission Date | 2024-04-11 |
The data cannot be downloaded as it has not yet been registered in the Human Genetic Resource Management Platform of MOST.
| File ID | File Title | Number/Samples | File Type | File Size | File Suffix | Download Times | Download |
|---|---|---|---|---|---|---|---|
| OMIX006223-01 | RRMM IND-like | 4 | Genetic Biomarkers | 2.9 MB | zip | 0 | Unavailable |